Event Raised More Than $250,000 for Pediatric Cancer Research and Treatment
February 23, 2023 03:44 PM Eastern Standard Time
NEW YORK–(BUSINESS WIRE)–The Dave Cantin Group(DCG), one of the largest automotive industry financial advisory services companies specializing in buy/sell transactions, announced today that its nonprofit partnership DCG Giving raised more than $250,000 at its first fundraising event of 2023. The dinner, headlined by legendary heavyweight champion Mike Tyson, took place at DCG’s exclusive, invitation-only VIP afterparty at the National Automobile Dealers Association (NADA) annual show in Dallas, at Del Frisco’s Double Eagle Steakhouse. The event auctioned off autographed boxing gloves by Mike Tyson.
“Even though more than 95% of children with certain subtypes will be cured, chance of survival is much less in many other subtypes. We work tirelessly to change those percentages.”Dr. Skapek
Proceeds from the DCG Giving fundraising event will directly support its partner, the Children’s Oncology Group (COG) – the world’s largest organization devoted exclusively to childhood and adolescent cancer research and treatment.
“Only about 4% of all federal funding for cancer research is spent on projects involving children’s cancers-that is simply not enough,” says Dave Cantin, Executive Chairman and CEO, DCG. “In 2022, DCG Giving donated more than half a million dollars to child and adolescent cancer research and treatment efforts, and we are excited to continue our efforts with more donations and events in 2023. ”
Also in attendance was Dr. Stephen X. Skapek, Chief, Division of Hematology/Oncology in the Department of Pediatrics at UT Southwestern Medical Center and a member of its Harold C. Simmons Comprehensive Cancer Center, a COG member. The Division is nationally distinguished for its design and conduct of NIH-funded multicenter clinical trials involving childhood cancer and blood disease.
“Childhood cancer is not just one disease. There are actually dozens of subtypes,” Dr. Skapek says. “Even though more than 95% of children with certain subtypes will be cured, chance of survival is much less in many other subtypes. We work tirelessly to change those percentages.”
He added, “From identifying proteins that can be ‘targeted’ as novel therapies in childhood cancer to understanding how certain cancer-causing mutations influence the metabolism in childhood brain tumors and certain types of sarcomas, our research remains in the forefront of diagnosing and caring for infants, children, and adolescents with cancer and blood disorders.”
DCG Giving’s fundraising proceeds support state-of-the-art research and treatment for children with cancer in communities nationwide, hallmarking DCG Giving’s mission to the 3 C’s: Children, Cancer, and Community. Visit DCG Giving to learn more and donate.